CD40 stimulates a "feed-forward" NF-κB-driven molecular pathway that regulates IFN-β expression in carcinoma cells

Journal of Immunology

Volumn 188, Issue 11, 2012, Pages 5521-5527

  Moschonas, Aristides ^a,b   Ioannou, Marina ^a,b   Eliopoulos, Aristides G ^a,b  

^a UNIVERSITY OF CRETE   (Greece)

^b INSTITUTE OF MOLECULAR BIOLOGY AND BIOTECHNOLOGY   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; CD40 ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON REGULATORY FACTOR 1; INTERFERON REGULATORY FACTOR 7; MEMBRANE PROTEIN; TRANSCRIPTION FACTOR RELA; UNCLASSIFIED DRUG; VIPERIN;

ARTICLE; BLADDER CARCINOMA; CANCER CELL CULTURE; CELL STRAIN HEK293; EMBRYO; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; KERATINOCYTE; POSITIVE FEEDBACK; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN SYNTHESIS; RECEPTOR OCCUPANCY; UPREGULATION;

ANTIGENS, CD40; CARCINOMA; CELL LINE, TRANSFORMED; CELL LINE, TUMOR; FEEDBACK, PHYSIOLOGICAL; GENE EXPRESSION REGULATION; HEK293 CELLS; HUMANS; INTERFERON-BETA; NF-KAPPA B; SIGNAL TRANSDUCTION; URINARY BLADDER NEOPLASMS;

EID: 84862094248     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1200133     Document Type: Article

References (52)

1. Trinchieri, G. 2010. Type I interferon: friend or foe? J. Exp. Med. 207: 2053-2063.
2. Trinchieri, G., and D. Santoli. 1978. Anti-viral activity induced by culturing lymphocytes with tumor-derived or virus-transformed cells: enhancement of human natural killer cell activity by interferon and antagonistic inhibition of susceptibility of target cells to lysis. J. Exp. Med. 147: 1314-1333. (Pubitemid 8328674)
3. Colonna, M., G. Trinchieri, and Y. J. Liu. 2004. Plasmacytoid dendritic cells in immunity. Nat. Immunol. 5: 1219-1226. (Pubitemid 41057736)
4. Nunez, N. G., V. Andreani, M. I. Crespo, D. A. Nocera, M. L. Breser, G. Moron, L. Dejager, C. Libert, V. Rivero, and M. Maccioni. 2012. IFN β produced by TLR4-activated tumor cells is involved in improving the antitumoral immune response. Cancer Res. 72: 592-603.
5. Nguyen, K. B., W. T. Watford, R. Salomon, S. R. Hofmann, G. C. Pien, A. Morinobu, M. Gadina, J. J. O'Shea, and C. A. Biron. 2002. Critical role for STAT4 activation by type 1 interferons in the interferon-gamma response to viral infection. Science 297: 2063-2066.
6. Swann, J. B., Y. Hayakawa, N. Zerafa, K. C. Sheehan, B. Scott, R. D. Schreiber, P. Hertzog, and M. J. Smyth. 2007. Type I IFN contributes to NK cell homeostasis, activation, and antitumor function. J. Immunol. 178: 7540-7549. (Pubitemid 46898022)
7. Elgueta, R., M. J. Benson, V. C. de Vries, A. Wasiuk, Y. Guo, and R. J. Noelle. 2009. Molecular mechanism and function of CD40/CD40L engagement in the immune system. Immunol. Rev. 229: 152-172.
8. Ferrari, S., S. Giliani, A. Insalaco, A. Al-Ghonaium, A. R. Soresina, M. Loubser, M. A. Avanzini, M. Marconi, R. Badolato, A. G. Ugazio, et al. 2001. Mutations of CD40 gene cause an autosomal recessive form of immunodeficiency with hyper IgM. Proc. Natl. Acad. Sci. USA 98: 12614-12619. (Pubitemid 33019994)
9. Aruffo, A., M. Farrington, D. Hollenbaugh, X. Li, A. Milatovich, S. Nonoyama, J. Bajorath, L. S. Grosmaire, R. Stenkamp, M. Neubauer, et al. 1993. The CD40 ligand, gp39, is defective in activated T cells from patients with X-linked hyper- IgM syndrome. Cell 72: 291-300. (Pubitemid 23044943)
10. Hayward, A. R., J. Levy, F. Facchetti, L. Notarangelo, H. D. Ochs, A. Etzioni, J. Y. Bonnefoy, M. Cosyns, and A. Weinberg. 1997. Cholangiopathy and tumors of the pancreas, liver, and biliary tree in boys with X-linked immunodeficiency with hyper-IgM. J. Immunol. 158: 977-983. (Pubitemid 127492679)
11. Ruby, J., H. Bluethmann, M. Aguet, and I. A. Ramshaw. 1995. CD40 ligand has potent antiviral activity. Nat. Med. 1: 437-441.
12. Loskog, A. S., and A. G. Eliopoulos. 2009. The Janus faces of CD40 in cancer. Semin. Immunol. 21: 301-307.
13. Vonderheide, R. H. 2007. Prospect of targeting the CD40 pathway for cancer therapy. Clin. Cancer Res. 13: 1083-1088. (Pubitemid 46424046)
14. Hill, S. C., S. J. Youde, S. Man, G. R. Teale, A. J. Baxendale, A. Hislop, C. C. Davies, D. M. Luesley, A. M. Blom, A. B. Rickinson, et al. 2005. Activation of CD40 in cervical carcinoma cells facilitates CTL responses and augments chemotherapy-induced apoptosis. J. Immunol. 174: 41-50. (Pubitemid 40007390)
15. Moschonas, A., M. Kouraki, P. G. Knox, E. Thymiakou, D. Kardassis, and A. G. Eliopoulos. 2008. CD40 induces antigen transporter and immunoproteasome gene expression in carcinomas via the coordinated action of NF-κB and of NF-κB-mediated de novo synthesis of IRF-1. Mol. Cell. Biol. 28: 6208-6222.
16. Fujita, T., Y. Kimura, M. Miyamoto, E. L. Barsoumian, and T. Taniguchi. 1989. Induction of endogenous IFN-α and IFN-β genes by a regulatory transcription factor, IRF-1. Nature 337: 270-272. (Pubitemid 19030564)
17. Yarilina, A., K. H. Park-Min, T. Antoniv, X. Hu, and L. B. Ivashkiv. 2008. TNF activates an IRF1-dependent autocrine loop leading to sustained expression of chemokines and STAT1-dependent type I interferon-response genes. Nat. Immunol. 9: 378-387. (Pubitemid 351405107)
18. Ford, E., and D. Thanos. 2010. The transcriptional code of human IFN-β gene expression. Biochim. Biophys. Acta 1799: 328-336.
19. Munshi, N., M. Merika, J. Yie, K. Senger, G. Chen, and D. Thanos. 1998. Acetylation of HMG I(Y) by CBP turns off IFN β expression by disrupting the enhanceosome. Mol. Cell 2: 457-467. (Pubitemid 128381298)
20. Maniatis, T., J. V. Falvo, T. H. Kim, T. K. Kim, C. H. Lin, B. S. Parekh, and M. G. Wathelet. 1998. Structure and function of the interferon-β enhanceosome. Cold Spring Harb. Symp. Quant. Biol. 63: 609-620.
21. Saitoh, T., T. Satoh, N. Yamamoto, S. Uematsu, O. Takeuchi, T. Kawai, and S. Akira. 2011. Antiviral protein Viperin promotes Toll-like receptor 7- and Toll-like receptor 9-mediated type I interferon production in plasmacytoid dendritic cells. Immunity 34: 352-363.
22. Davies, C. C., T. W. Mak, L. S. Young, and A. G. Eliopoulos. 2005. TRAF6 is required for TRAF2-dependent CD40 signal transduction in nonhemopoietic cells. Mol. Cell. Biol. 25: 9806-9819. (Pubitemid 41572731)
23. Bishop, G. A. 2004. The multifaceted roles of TRAFs in the regulation of B-cell function. Nat. Rev. Immunol. 4: 775-786. (Pubitemid 39336294)
24. Bishop, G. A., C. R. Moore, P. Xie, L. L. Stunz, and Z. J. Kraus. 2007. TRAF proteins in CD40 signaling. Adv. Exp. Med. Biol. 597: 131-151.
25. Eliopoulos, A. G. 2008. Cell signaling: "make and brake" in signaling. Science 321: 648-649.
26. Pullen, S. S., M. E. Labadia, R. H. Ingraham, S. M. McWhirter, D. S. Everdeen, T. Alber, J. J. Crute, and M. R. Kehry. 1999. High-affinity interactions of tumor necrosis factor receptor-associated factors (TRAFs) and CD40 require TRAF trimerization and CD40 multimerization. Biochemistry 38: 10168-10177.
27. Rothe, M., V. Sarma, V. M. Dixit, and D. V. Goeddel. 1995. TRAF2-mediated activation of NF-kB by TNF receptor 2 and CD40. Science 269: 1424-1427.
28. Coope, H. J., P. G. Atkinson, B. Huhse, M. Belich, J. Janzen, M. J. Holman, G. G. Klaus, L. H. Johnston, and S. C. Ley. 2002. CD40 regulates the processing of NF-kappaB2 p100 to p52. EMBO J. 21: 5375-5385. (Pubitemid 35231017)
29. Barré, B., and N. D. Perkins. 2010. The Skp2 promoter integrates signaling through the NF-kappaB, p53, and Akt/GSK3beta pathways to regulate autophagy and apoptosis. Mol. Cell 38: 524-538.
30. Munshi, N., T. Agalioti, S. Lomvardas, M. Merika, G. Chen, and D. Thanos. 2001. Coordination of a transcriptional switch by HMGI(Y) acetylation. Science 293: 1133-1136. (Pubitemid 32758093)
31. Thanos, D., and T. Maniatis. 1995. Identification of the rel family members required for virus induction of the human beta interferon gene. Mol. Cell. Biol. 15: 152-164. (Pubitemid 24379911)
32. Apostolou, E., and D. Thanos. 2008. Virus Infection Induces NF-kappaB-dependent interchromosomal associations mediating monoallelic IFN-beta gene expression. Cell 134: 85-96. (Pubitemid 351905745)
33. Wang, X., S. Hussain, E. J. Wang, X. Wang, M. O. Li, A. García-Sastre, and A. A. Beg. 2007. Lack of essential role of NF-kappa B p50, RelA, and cRel subunits in virus-induced type 1 IFN expression. J. Immunol. 178: 6770-6776. (Pubitemid 46847401)
34. Wang, J., S. H. Basagoudanavar, X. Wang, E. Hopewell, R. Albrecht, A. García- Sastre, S. Balachandran, and A. A. Beg. 2010. NF-kappa B RelA subunit is crucial for early IFN-beta expression and resistance to RNA virus replication. J. Immunol. 185: 1720-1729.
35. Stirnweiss, A., A. Ksienzyk, K. Klages, U. Rand, M. Grashoff, H. Hauser, and A. Kröger. 2010. IFN regulatory factor-1 bypasses IFN-mediated antiviral effects through viperin gene induction. J. Immunol. 184: 5179-5185.
36. Kishore, N., C. Sommers, S. Mathialagan, J. Guzova, M. Yao, S. Hauser, K. Huynh, S. Bonar, C. Mielke, L. Albee, et al. 2003. A selective IKK-2 inhibitor blocks NF-κB-dependent gene expression in interleukin-1β-stimulated synovial fibroblasts. J. Biol. Chem. 278: 32861-32871. (Pubitemid 37055728)
37. Knox, P. G., C. C. Davies, M. Ioannou, and A. G. Eliopoulos. 2011. The death domain kinase RIP1 links the immunoregulatory CD40 receptor to apoptotic signaling in carcinomas. J. Cell Biol. 192: 391-399.
38. Malmström, P. U., A. S. Loskog, C. A. Lindqvist, S. M. Mangsbo, M. Fransson, A. Wanders, T. Gårdmark, and T. H. Tötterman. 2010. AdCD40L immunogene therapy for bladder carcinoma - the first phase I/IIa trial. Clin. Cancer Res. 16: 3279-3287.
39. Vardouli, L., C. Lindqvist, K. Vlahou, A. S. Loskog, and A. G. Eliopoulos. 2009. Adenovirus delivery of human CD40 ligand gene confers direct therapeutic effects on carcinomas. Cancer Gene Ther. 16: 848-860.
40. Takaoka, A., S. Hayakawa, H. Yanai, D. Stoiber, H. Negishi, H. Kikuchi, S. Sasaki, K. Imai, T. Shibue, K. Honda, and T. Taniguchi. 2003. Integration of interferon-a/b signalling to p53 responses in tumour suppression and antiviral defence. Nature 424: 516-523. (Pubitemid 36975769)
41. Grups, J. W., and H. G. Frohmüller. 1988. Antiproliferative effects of interferons against human bladder carcinoma cell lines in vitro. Urol. Int. 43: 265-268.
42. Honda, K., H. Yanai, H. Negishi, M. Asagiri, M. Sato, T. Mizutani, N. Shimada, Y. Ohba, A. Takaoka, N. Yoshida, and T. Taniguchi. 2005. IRF-7 is the master regulator of type-I interferon-dependent immune responses. Nature 434: 772-777. (Pubitemid 44739521)
43. Schmitz, F., A. Heit, S. Guggemoos, A. Krug, J. Mages, M. Schiemann, H. Adler, I. Drexler, T. Haas, R. Lang, and H. Wagner. 2007. Interferon-regulatory- factor 1 controls Toll-like receptor 9-mediated IFN-β production in myeloid dendritic cells. Eur. J. Immunol. 37: 315-327. (Pubitemid 46915571)
44. French, R. R., H. T. C. Chan, A. L. Tutt, and M. J. Glennie. 1999. CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help. Nat. Med. 5: 548-553. (Pubitemid 29220214)
45. Takahashi, S., R. F. Rousseau, P. Yotnda, Z. Mei, G. Dotti, D. Rill, R. Hurwitz, F. Marini, M. Andreeff, and M. K. Brenner. 2001. Autologous antileukemic immune response induced by chronic lymphocytic leukemia B cells expressing the CD40 ligand and interleukin 2 transgenes. Hum. Gene Ther. 12: 659-670. (Pubitemid 32506944)
46. Kikuchi, T., M. A. S. Moore, and R. G. Crystal. 2000. Dendritic cells modified to express CD40 ligand elicit therapeutic immunity against preexisting murine tumors. Blood 96: 91-99. (Pubitemid 30456456)
47. Loskog, A., H. Dzojic, S. Vikman, C. Ninalga, M. Essand, O. Korsgren, and T. H. Totterman. 2004. Adenovirus CD40 ligand gene therapy counteracts immune escape mechanisms in the tumor Microenvironment. J. Immunol. 172: 7200-7205. (Pubitemid 38669165)
48. Beatty, G. L., E. G. Chiorean, M. P. Fishman, B. Saboury, U. R. Teitelbaum, W. Sun, R. D. Huhn, W. Song, D. Li, L. L. Sharp, et al. 2011. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 331: 1612-1616.
49. Perkins, N. D. 2004. NF-kB: tumor promoter or suppressor? Trends Cell Biol. 14: 64-69.
50. Chin, K. C., and P. Cresswell. 2001. Viperin (cig5), an IFN-inducible antiviral protein directly induced by human cytomegalovirus. Proc. Natl. Acad. Sci. USA 98: 15125-15130. (Pubitemid 34013980)
51. Helbig, K. J., D. T. Lau, L. Semendric, H. A. Harley, and M. R. Beard. 2005. Analysis of ISG expression in chronic hepatitis C identifies viperin as a potential antiviral effector. Hepatology 42: 702-710. (Pubitemid 41233665)
52. Rivieccio, M. A., H. S. Suh, Y. Zhao, M. L. Zhao, K. C. Chin, S. C. Lee, and C. F. Brosnan. 2006. TLR3 ligation activates an antiviral response in human fetal astrocytes: a role for viperin/cig5. J. Immunol. 177: 4735-4741. (Pubitemid 44469807)